The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 06, 2024
Filed:
Jan. 05, 2021
Glycom A/s, Hørsholm, DK;
Bruce McConnell, La Tour de Peilz, CH;
Louise Kristine Vigsnæs, København, DK;
Emma Elison, Hjärup, SE;
Glycom A/S, Hørsholm, DK;
Abstract
A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and mixtures thereof. The method further includes increasing the relative abundance ofin the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.